Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD)

78 filings reported holding PRLD - Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share as of Q4 2024.
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) has 59 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 32.1M shares of 44.2M outstanding shares and own 72.76% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (10.9M shares), BAKER BROS. ADVISORS LP (10.1M shares), Boxer Capital Management, LLC (1.71M shares), BlackRock, Inc. (1.07M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.03M shares), VANGUARD GROUP INC (1.01M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (667K shares), RENAISSANCE TECHNOLOGIES LLC (635K shares), MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (494K shares), and ACADIAN ASSET MANAGEMENT LLC (485K shares).
This table shows the top 59 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.